A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease (Q36467473)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

phase I clinical trial

0 references

adaptive radiation therapy

0 references

Malcolm Brenner

2

object named as

Brenner MK

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

3

object named as

Heslop HE

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

author name string

Gottlieb DJ

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Bianchi AC

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Bello-Fernandez C

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Mehta AB

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Newland AC

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Galazka AR

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Scott EM

9

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Hoffbrand AV

10

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

1 October 1989

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

60

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

610-615

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Clinical investigation of human alpha interferon in chronic myelogenous leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247111

28 June 2018

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247111

28 June 2018

Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247111

28 June 2018

Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2247111

28 June 2018

Human bone marrow colony growth in agar-gel

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro analysis of the interactions of recombinant IL-2 with regenerating lymphoid and myeloid cells after allogeneic marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of acute myelogenous leukemia. A prospective controlled trial of bone marrow transplantation versus consolidation chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autologous bone marrow transplantation for acute leukaemia in remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy v marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 2 enhances cytotoxic cell function in vitro after T-cell depleted marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The fate of interleukin-2 after in vivo administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/2803933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BJC.1989.324

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36467473&oldid=2198935831"